Manufacturer of Controlled Substances Registration: AMRI Rensselaer Inc., 57387-57388 [2015-24122]
Download as PDF
<![CDATA[
Federal Register / Vol. 80, No. 184 / Wednesday, September 23, 2015 / Notices
INTERNATIONAL TRADE
COMMISSION
[Investigation Nos. 701–TA–465 and 731–
TA–1161 (Review)]
Certain Steel Grating From China;
Scheduling of an Expedited Five-Year
Review
United States International
Trade Commission.
ACTION: Notice.
AGENCY:
The Commission hereby gives
notice of the scheduling of an expedited
review pursuant to the Tariff Act of
1930 (‘‘the Act’’) to determine whether
revocation of the antidumping duty and
countervailing duty orders on certain
steel grating from China would be likely
to lead to continuation or recurrence of
material injury within a reasonably
foreseeable time.
DATES: Effective date: September 4,
2015.
SUMMARY:
FOR FURTHER INFORMATION CONTACT:
Charles Yost ((202) 205–3432), Office of
Investigations, U.S. International Trade
Commission, 500 E Street SW.,
Washington, DC 20436. Hearingimpaired persons can obtain
information on this matter by contacting
the Commission’s TDD terminal on 202–
205–1810. Persons with mobility
impairments who will need special
assistance in gaining access to the
Commission should contact the Office
of the Secretary at 202–205–2000.
General information concerning the
Commission may also be obtained by
accessing its internet server (https://
www.usitc.gov). The public record for
this review may be viewed on the
Commission’s electronic docket (EDIS)
at https://edis.usitc.gov.
SUPPLEMENTARY INFORMATION:
mstockstill on DSK4VPTVN1PROD with NOTICES
Background
On September 4, 2015, the
Commission determined that the
domestic interested party group
response to its notice of institution (80
FR 31071, June 1, 2015) of the subject
five-year review was adequate and that
the respondent interested party group
response was inadequate. The
Commission did not find any other
circumstances that would warrant
conducting a full review.1 Accordingly,
the Commission determined that it
would conduct an expedited review
1 A record of the Commissioners’ votes, the
Commission’s statement on adequacy, and any
individual Commissioner’s statements will be
available from the Office of the Secretary and at the
Commission’s Web site.
VerDate Sep<11>2014
18:00 Sep 22, 2015
Jkt 235001
pursuant to section 751(c)(3) of the
Tariff Act of 1930 (19 U.S.C. 1675(c)(3)).
For further information concerning
the conduct of this review and rules of
general application, consult the
Commission’s Rules of Practice and
Procedure, part 201, subparts A and B
(19 CFR part 201), and part 207,
subparts A, D, E, and F (19 CFR part
207).
Staff Report
A staff report containing information
concerning the subject matter of the
review will be placed in the nonpublic
record on September 30, 2015, and
made available to persons on the
Administrative Protective Order service
list for this review. A public version
will be issued thereafter, pursuant to
section 207.62(d)(4) of the
Commission’s rules.
Written Submissions
As provided in section 207.62(d) of
the Commission’s rules, interested
parties that are parties to the review and
that have provided individually
adequate responses to the notice of
institution,2 and any party other than an
interested party to the review may file
written comments with the Secretary on
what determination the Commission
should reach in the review. Comments
are due on or before October 5, 2015 and
may not contain new factual
information. Any person that is neither
a party to the five-year review nor an
interested party may submit a brief
written statement (which shall not
contain any new factual information)
pertinent to the review by October 5,
2015. However, should the Department
of Commerce extend the time limit for
its completion of the final results of its
review, the deadline for comments
(which may not contain new factual
information) on Commerce’s final
results is three business days after the
issuance of Commerce’s results. If
comments contain business proprietary
information (BPI), they must conform
with the requirements of sections 201.6,
207.3, and 207.7 of the Commission’s
rules. Please be aware that the
Commission’s rules with respect to
filing have changed. The most recent
amendments took effect on July 25,
2014. See 79 FR 35920 (June 25, 2014),
and the revised Commission Handbook
on E-filing, available from the
2 The Commission has found the responses
submitted by the Metal Grating Coalition and its
individual member, Alabama Metal Industries
Corporation, fisher & Ludlow, Inc., Harsco
Industrial IKG, Interstate Gratings, LLC, and Ohio
Gratings, Inc. to be individually adequate.
Comments from other interested parties will not be
accepted (see 19 CFR 207.62(d)(2)).
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
57387
Commission’s Web site at https://
edis.usitc.gov.
In accordance with sections 201.16(c)
and 207.3 of the rules, each document
filed by a party to the review must be
served on all other parties to the review
(as identified by either the public or BPI
service list), and a certificate of service
must be timely filed. The Secretary will
not accept a document for filing without
a certificate of service.
Authority: This review is being conducted
under authority of title VII of the Tariff Act
of 1930; this notice is published pursuant to
section 207.62 of the Commission’s rules.
Issued: September 17, 2015.
By order of the Commission.
Lisa R. Barton,
Secretary the Commission.
[FR Doc. 2015–24081 Filed 9–22–15; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Manufacturer of Controlled
Substances Registration: AMRI
Rensselaer Inc.
ACTION:
Notice of registration.
AMRI Rensselaer, Inc. applied
to be registered as a manufacturer of
certain basic classes of controlled
substances. The Drug Enforcement
Administration (DEA) grants AMRI
Rensselaer, Inc. registration as a
manufacturer of those controlled
substances.
SUPPLEMENTARY INFORMATION: By notice
dated April 14, 2015, and published in
the Federal Register on April 22, 2015,
80 FR 22560, AMRI Rensselaer, Inc., 33
Riverside Avenue, Rensselaer, New
York 12144 applied to be registered as
a manufacturer of certain basic classes
of controlled substances. No comments
or objections were submitted for this
notice.
The DEA has considered the factors in
21 U.S.C. 823(a) and determined that
the registration of AMRI Rensselaer, Inc.
to manufacture the basic classes of
controlled substances is consistent with
the public interest and with United
States obligations under international
treaties, conventions, or protocols in
effect on May 1, 1971. The DEA
investigated the company’s maintenance
of effective controls against diversion by
inspecting and testing the company’s
physical security systems, verifying the
company’s compliance with state and
local laws, and reviewing the company’s
background and history.
SUMMARY:
E:\FR\FM\23SEN1.SGM
23SEN1
57388
Federal Register / Vol. 80, No. 184 / Wednesday, September 23, 2015 / Notices
Therefore, pursuant to 21 U.S.C.
823(a), and in accordance with 21 CFR
1301.33, the above-named company is
granted registration as a bulk
manufacturer of the basic classes of
controlled substances:
Controlled substance
Schedule
Marihuana (7360) .......................
Tetrahydrocannabinols (7370) ....
Amphetamine (1100) ..................
Lisdexamfetamine (1205) ...........
Methylphenidate (1724) ..............
Pentobarbital (2270) ...................
4-Anilino-N-phenethyl-4-piperidine (8333).
Meperidine (9230) ......................
Fentanyl (9801) ..........................
I
I
II
II
II
II
II
II
II
The company plans to manufacture
bulk controlled substances for use in
product development and for
distribution to its customers.
In reference to drug code 7360
(marihuana), and 7370 (THC), the
company plans to bulk manufacture
these drugs as synthetic. No other
activity for this drug code is authorized
for this registration.
Dated: September 16, 2015.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2015–24122 Filed 9–22–15; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Bulk Manufacturer of Controlled
Substances Application: Mallinckrodt
LLC
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration in
accordance with 21 CFR 1301.33(a) on
or before November 23, 2015.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/ODXL, 8701
Morrissette Drive, Springfield, Virginia
22152. Request for hearings should be
sent to: Drug Enforcement
Administration, Attention: Hearing
Clerk/LJ, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The
Attorney General has delegated her
authority under the Controlled
mstockstill on DSK4VPTVN1PROD with NOTICES
DATES:
VerDate Sep<11>2014
18:00 Sep 22, 2015
Jkt 235001
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Deputy Assistant
Administrator of the DEA Office of
Diversion Control (‘‘Deputy Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.33(a), this is notice that on July 21,
2015, Mallinckrodt LLC, 3600 North
Second Street, Saint. Louis, Missouri
63147 applied to be registered as a bulk
manufacturer of the following basic
classes of controlled substances:
Controlled substance
Gamma
Hydroxybutyric
Acid
(2010).
Tetrahydrocannabinols (7370) .....
Codeine-N-oxide (9053) ...............
Dihydromorphine (9145) ...............
Difenoxin (9168) ...........................
Morphine-N-oxide (9307) .............
Normorphine (9313) .....................
Norlevorphanol (9634) ..................
Acetyl
Fentanyl
(N-(1phenethylpiperidin-4-yl)-Nphenylacetamide) (9821).
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Lisdexamfetamine (1205) .............
Methylphenidate (1724) ................
Nabilone (7379) ............................
4-Anilino-N-phenethyl-4-piperidine
(8333).
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Diphenoxylate (9170) ...................
Ecgonine (9180) ...........................
Hydrocodone (9193) .....................
Levorphanol (9220) ......................
Meperidine (9230) ........................
Methadone (9250) ........................
Methadone intermediate (9254) ...
Dextropropoxyphene, bulk (nondosage forms) (9273).
Morphine (9300) ...........................
Oripavine (9330) ...........................
Thebaine (9333) ...........................
Opium tincture (9630) ..................
Opium, powdered (9639) .............
Oxymorphone (9652) ...................
Noroxymorphone (9668) ..............
Alfentanil (9737) ...........................
Remifentanil (9739) ......................
Sufentanil (9740) ..........................
Tapentadol (9780) ........................
Fentanyl (9801) ............................
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
Schedule
I
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to manufacturer
bulk active pharmaceutical ingredients
(API) for distribution its customers.
Dated: September 16, 2015.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2015–24125 Filed 9–22–15; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Registration: Fisher Clinical Services,
Inc.
ACTION:
Notice of registration.
Fisher Clinical Services, Inc.
applied to be registered as an importer
of certain basic classes of controlled
substances. The Drug Enforcement
Administration (DEA) grants Fisher
Clinical Services, Inc. registration as an
importer of those controlled substances.
SUPPLEMENTARY INFORMATION: By notice
dated August 27, 2014, and published in
the Federal Register on September 4,
2014, 79 FR 52762, Fisher Clinical
Services, Inc., 700A–C Nestle Way,
Breinigsville, Pennsylvania 18031–1522
applied to be registered as an importer
of certain basic classes of controlled
substances. No comments or objections
were submitted for this notice.
The DEA has considered the factors in
21 U.S.C. 823, 952(a) and 958(a) and
determined that the registration of
Fisher Clinical Services, Inc. to import
the basic classes of controlled
substances is consistent with the public
interest and with United States
obligations under international treaties,
conventions, or protocols in effect on
May 1, 1971. The DEA investigated the
company’s maintenance of effective
controls against diversion by inspecting
and testing the company’s physical
security systems, verifying the
company’s compliance with state and
local laws, and reviewing the company’s
background and history.
Therefore, pursuant to 21 U.S.C.
952(a) and 958(a), and in accordance
with 21 CFR 1301.34, the above-named
company is granted registration as an
importer of the basic classes of
controlled substances:
SUMMARY:
Controlled substance
Methylphenidate (1724) ................
Levorphanol (9220) ......................
Noroxymorphone (9668) ..............
Tapentadol (9780) ........................
E:\FR\FM\23SEN1.SGM
23SEN1
Schedule
II
II
II
II
]]>Agencies
[Federal Register Volume 80, Number 184 (Wednesday, September 23, 2015)]
[Notices]
[Pages 57387-57388]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-24122]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Manufacturer of Controlled Substances Registration: AMRI
Rensselaer Inc.
ACTION: Notice of registration.
-----------------------------------------------------------------------
SUMMARY: AMRI Rensselaer, Inc. applied to be registered as a
manufacturer of certain basic classes of controlled substances. The
Drug Enforcement Administration (DEA) grants AMRI Rensselaer, Inc.
registration as a manufacturer of those controlled substances.
SUPPLEMENTARY INFORMATION: By notice dated April 14, 2015, and
published in the Federal Register on April 22, 2015, 80 FR 22560, AMRI
Rensselaer, Inc., 33 Riverside Avenue, Rensselaer, New York 12144
applied to be registered as a manufacturer of certain basic classes of
controlled substances. No comments or objections were submitted for
this notice.
The DEA has considered the factors in 21 U.S.C. 823(a) and
determined that the registration of AMRI Rensselaer, Inc. to
manufacture the basic classes of controlled substances is consistent
with the public interest and with United States obligations under
international treaties, conventions, or protocols in effect on May 1,
1971. The DEA investigated the company's maintenance of effective
controls against diversion by inspecting and testing the company's
physical security systems, verifying the company's compliance with
state and local laws, and reviewing the company's background and
history.
[[Page 57388]]
Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21
CFR 1301.33, the above-named company is granted registration as a bulk
manufacturer of the basic classes of controlled substances:
------------------------------------------------------------------------
Controlled substance Schedule
------------------------------------------------------------------------
Marihuana (7360).......................... I
Tetrahydrocannabinols (7370).............. I
Amphetamine (1100)........................ II
Lisdexamfetamine (1205)................... II
Methylphenidate (1724).................... II
Pentobarbital (2270)...................... II
4-Anilino-N-phenethyl-4-piperidine (8333). II
Meperidine (9230)......................... II
Fentanyl (9801)........................... II
------------------------------------------------------------------------
The company plans to manufacture bulk controlled substances for use
in product development and for distribution to its customers.
In reference to drug code 7360 (marihuana), and 7370 (THC), the
company plans to bulk manufacture these drugs as synthetic. No other
activity for this drug code is authorized for this registration.
Dated: September 16, 2015.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2015-24122 Filed 9-22-15; 8:45 am]
BILLING CODE 4410-09-P
